Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 3
1982 3
1983 3
1984 2
1985 10
1986 35
1987 47
1988 70
1989 93
1990 111
1991 115
1992 118
1993 175
1994 288
1995 301
1996 305
1997 295
1998 374
1999 397
2000 419
2001 381
2002 406
2003 458
2004 506
2005 693
2006 790
2007 761
2008 747
2009 793
2010 948
2011 1114
2012 1316
2013 1588
2014 1628
2015 1698
2016 1702
2017 1717
2018 1274
2019 606
2020 25
Text availability
Article attribute
Article type
Publication date

Search Results

20,074 results
Results by year
Filters applied: . Clear all
Page 1
TAM Receptor Tyrosine Kinases in Cancer Drug Resistance.
Vouri M, Hafizi S. Vouri M, et al. Cancer Res. 2017 Jun 1;77(11):2775-2778. doi: 10.1158/0008-5472.CAN-16-2675. Epub 2017 May 19. Cancer Res. 2017. PMID: 28526769 Free article. Review.
Molecular characterization of cancers with NTRK gene fusions.
Gatalica Z, Xiu J, Swensen J, Vranic S. Gatalica Z, et al. Mod Pathol. 2019 Jan;32(1):147-153. doi: 10.1038/s41379-018-0118-3. Epub 2018 Aug 31. Mod Pathol. 2019. PMID: 30171197 Free article.
NTRK-Fusions - A new kid on the block.
Märkl B, Hirschbühl K, Dhillon C. Märkl B, et al. Pathol Res Pract. 2019 Oct;215(10):152572. doi: 10.1016/j.prp.2019.152572. Epub 2019 Aug 1. Pathol Res Pract. 2019. PMID: 31400924 Review.
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL. Smith BD, et al. Cancer Cell. 2019 May 13;35(5):738-751.e9. doi: 10.1016/j.ccell.2019.04.006. Cancer Cell. 2019. PMID: 31085175
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O. Taylor J, et al. J Clin Invest. 2018 Aug 31;128(9):3819-3825. doi: 10.1172/JCI120787. Epub 2018 Aug 6. J Clin Invest. 2018. PMID: 29920189 Free PMC article.
Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome.
Xu L, Jensen H, Johnston JJ, Di Maria E, Kloth K, Cristea I, Sapp JC, Darling TN, Huryn LA, Tranebjærg L, Cinotti E, Kubisch C, Rødahl E, Bruland O, Biesecker LG, Houge G, Bredrup C. Xu L, et al. Am J Hum Genet. 2018 Dec 6;103(6):976-983. doi: 10.1016/j.ajhg.2018.10.013. Epub 2018 Nov 15. Am J Hum Genet. 2018. PMID: 30449416 Free PMC article.
A precision therapy against cancers driven by KIT/PDGFRA mutations.
Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C. Evans EK, et al. Sci Transl Med. 2017 Nov 1;9(414):eaao1690. doi: 10.1126/scitranslmed.aao1690. Sci Transl Med. 2017. PMID: 29093181 Clinical Trial.
20,074 results
Jump to page
Feedback